These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 15285882)
21. Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy. Carlsson J; Eriksson V; Stenerlöw B; Lundqvist H Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1185-95. PubMed ID: 16718515 [TBL] [Abstract][Full Text] [Related]
22. Dosage and response in radiopharmaceutical therapy of painful osseous metastases. Silberstein EB J Nucl Med; 1996 Feb; 37(2):249-52. PubMed ID: 8667054 [No Abstract] [Full Text] [Related]
23. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. Barone R; Borson-Chazot F; Valkema R; Walrand S; Chauvin F; Gogou L; Kvols LK; Krenning EP; Jamar F; Pauwels S J Nucl Med; 2005 Jan; 46 Suppl 1():99S-106S. PubMed ID: 15653658 [TBL] [Abstract][Full Text] [Related]
24. Dosimetry in Peptide radionuclide receptor therapy: a review. Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G J Nucl Med; 2006 Sep; 47(9):1467-75. PubMed ID: 16954555 [TBL] [Abstract][Full Text] [Related]
25. Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose. Lawhn-Heath C; Hope TA; Martinez J; Fung EK; Shin J; Seo Y; Flavell RR Lancet Oncol; 2022 Feb; 23(2):e75-e87. PubMed ID: 35114134 [TBL] [Abstract][Full Text] [Related]
26. [Resorptive radioactive preparations]. Dedenkov AN Med Radiol (Mosk); 1977 May; 22(5):90-4. PubMed ID: 327189 [No Abstract] [Full Text] [Related]
27. Tumor control probability for tumor therapy with beta radionuclide interstitial injection. Chen Y; Geng J; Tian J; He Y; Chen S Biomed Mater Eng; 2004; 14(3):333-5. PubMed ID: 15299245 [No Abstract] [Full Text] [Related]
31. Proceedings of the 1st International Symposium on Radionuclide Therapy and Radiopharmaceutical Dosimetry. September 4-8, 2004, Helsinki, Finland. Cancer Biother Radiopharm; 2005 Feb; 20(1):41-118. PubMed ID: 15778578 [No Abstract] [Full Text] [Related]
35. Radiolabeled antibodies: results and potential in cancer therapy. Order SE; Sleeper AM; Stillwagon GB; Klein JL; Leichner PK Cancer Res; 1990 Feb; 50(3 Suppl):1011s-1013s. PubMed ID: 2404579 [TBL] [Abstract][Full Text] [Related]
36. Targeted radionuclide therapy: theoretical study of the relationship between tumour control probability and tumour radius for a 32P/33P radionuclide cocktail. Lechner A; Blaickner M; Gianolini S; Poljanc K; Aiginger H; Georg D Phys Med Biol; 2008 Apr; 53(7):1961-74. PubMed ID: 18354241 [TBL] [Abstract][Full Text] [Related]
37. Dosimetry is alive and well. Lassmann M; Strigari L; Bardiès M Cancer Biother Radiopharm; 2010 Oct; 25(5):593-5. PubMed ID: 20854209 [No Abstract] [Full Text] [Related]
38. Dose-rate effects in biologically targeted radiotherapy. O'Donoghue JA; Wheldon TE Int J Radiat Biol; 1989 Nov; 56(5):745-9. PubMed ID: 2573672 [No Abstract] [Full Text] [Related]